n engl j med 372;19 nejm.org May 7, 2015 1802 T h e ne w e ngl a nd jou r na l o f m e dicine T he decision to initiate or forgo potentially lifesaving treatment in infants who are born near the limit of viability is extremely difficult. 1, 2 Clinicians recognize that in some cases, the infant is too immature for treatment to be effective, whereas in other cases, treatment is clearly indicated. Yet, in many cases, it is unclear whether treatment is in the infant's best interest. 3, 4 Although factors such as the infant's birth weight and sex, plurality of birth (singleton vs. multiple), and exposure to antenatal glucocorticoids affect the prognosis of extremely preterm infants, 5,6 many groups still make recommendations about active treatment that are based primarily on gestational age at birth. 2, [7] [8] [9] [10] [11] [12] Active intervention for infants born before 22 weeks of gestation is generally not recommended, whereas the approach for infants born at or after 22 weeks of gestation varies. In the United States, both the American Academy of Pediatrics (AAP) and the American Congress of Obstetricians and Gynecologists (ACOG) recommend that clinicians and families make individualized decisions about treating extremely preterm infants on the basis of parental preference and the most recent data available regarding survival and morbidity. 4, 13 Counseling of families who are facing an extremely preterm birth is complicated by wide variation in outcomes. In two studies, survival estimates range from 1 to 52% among infants born at 23 weeks of gestation and from 31 to 67% among infants born at 24 weeks of gestation. 14, 15 Reported rates of neurodevelopmental impairment among children who were born extremely preterm also vary significantly. 16 The recent summary of a workshop held by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine, the AAP, and the ACOG on extremely preterm birth suggests that variation in reported outcomes may, in part, reflect differences in hospital practices regarding the initiation of either active treatment or comfort care. 2 To investigate this possibility and its implications, we analyzed data collected for infants who were born at hospitals included in the NICHD Neonatal Research Network (NRN) to identify variation in hospital rates of active treatment and the relationship between active treatment and outcomes at 18 to 22 months of corrected age.
Me thods
We studied infants who were born between April 1, 2006, and March 31, 2011 , at 24 hospitals included in the NRN. The NRN consists of clinical centers of various sizes and in several U.S. regions, with diverse patient demographics, clinical practices, and outcomes. 17, 18 Hospitals included in the study analysis contributed data for the entire study period.
We collected data for liveborn infants who were born before 27 weeks of gestation, including those who died in the delivery room. Data were collected for infants born before 22 weeks of gestation if they weighed 400 g or more; there was no minimum birth weight for infants born at or after 22 weeks of gestation. A total of 213 infants with recognized syndromes or major congenital malformations were excluded, because factors besides prematurity may have influenced the prognosis and treatment decisions for these infants. Three additional infants were excluded owing to missing data about interventions administered in the delivery room.
Data Collection
Trained research personnel at each hospital obtained data for all liveborn infants. 19 Demographic and clinical information was extracted from medical records. Gestational age at birth was determined by identifying the dates of the mother's last menstrual period and examining fetal ultrasound images, or if those methods were unavailable, by estimation after birth. 20 Birth weight for gestational age was compared with sex-specific growth curves. 21 The institutional review board at each participating site approved NRN in-hospital and follow-up protocols. Written informed consent from a parent or guardian was obtained for the follow-up protocol at 20 hospitals and for the inhospital protocol at 2 hospitals. For all other hospitals, the institutional review board approved a waiver of consent. The second and fourth authors had full access to all data and were responsible for the data analysis and reporting.
Active Treatment
Infants were considered to have received active treatment if they received any of the following interventions: surfactant therapy, tracheal intubation, ventilatory support (including continuous positive airway pressure, bag-valve-mask ventilation, or mechanical ventilation), parenteral nutrition, epinephrine, or chest compressions. We focused on the specific decision to initiate or forgo active treatment after birth and thus did not include obstetrical treatment or later decisions to withdraw treatment (after an infant's response to treatment could be gauged) in our definition.
Outcomes
Data on survival and neurodevelopmental impairment were collected at 18 to 22 months of corrected age. Neurodevelopmental assessment was performed by annually certified examiners and consisted of a structured neurologic examination and developmental and behavioral tests, which have been described previously. 22, 23 Severe impairment was defined as a cognitive or motor score on the Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) of less than 70 (i.e., >2 SD below the scale mean; mean [±SD], 100±15), severe cerebral palsy, a Gross Motor Function Classification System (GMFCS) level of 4 or 5 (on a scale of 0 [normal] to 5 [most impaired]), bilateral blindness (visual acuity, <20/200), or severe hearing impairment that cannot be corrected with bilateral amplification. Moderate impairment was defined as a Bayley-III cognitive or motor score of 70 to 84, (i.e., 1 to 2 SD below the scale mean), moderate cerebral palsy, or a GMFCS level of 2 or 3. Bayley-III motor scores were ascertained beginning in 2010; all other criteria were assessed throughout the study period. Because impairment is a risk only for infants who survive, we used the following outcomes in our models: survival, survival without severe impairment, and survival without moderate or severe impairment.
Statistical Analysis
We used the chi-square test or Fisher's exact test (if the cell size was <5) to compare the differences in demographic and clinical characteristics between infants who received active treatment and those who did not. We calculated overall rates of active treatment (percentage of all infants who received active treatment) by gestational age at birth in both days and weeks. We used Wilson's method to derive 95% confidence intervals. 24 We used multivariable multilevel logisticregression models to assess clustering of active treatment at the hospital level, by gestational age at birth, after accounting for differences in patient characteristics. Models included infant-level receipt of active treatment as a binary outcome and were adjusted for characteristics that were known before or shortly after birth, including the infant's birth weight (in grams), sex, plurality of birth (singleton vs. multiple), and 1-minute Apgar score (≤3 vs. >3) and the mother's age (≤19 years vs. >19 years), race (white, black, or other), ethnic group (Hispanic vs. non-Hispanic), enrollment in private health insurance (yes vs. no), receipt of prenatal care (≥1 visit vs. no visits), receipt of antenatal glucocorticoids (yes vs. no), and status with respect to hypertension (including preexisting hypertension, gestational hypertension, preeclampsia, and eclampsia) (yes vs. no), insulin-dependent diabetes (yes vs. no), and chorioamnionitis (yes vs. no). We calculated the intraclass correlation coefficient (ICC) statistic, which represents between-group variation as a proportion of all variation of a dependent variable when data are analyzed by group (e.g., hospital). Using the models described above, we calculated the ICC for active treatment (i.e., the proportion of variation in active treatment that was attributable to an infant's hospital of birth) by gestational age at birth. 25 To determine how hospital practices regarding the initiation of active treatment in extremely preterm infants relate to the outcomes of survival and survival without impairment by gestational age at birth, we compared pairs of multilevel logistic-regression models for each of the three specified outcomes. 25 In these models, the infant was the unit of analysis and the outcome was the dependent variable. Each pair of models consisted of one model that included the hospital rate of active treatment (percentage of infants at a given hospital who received active treatment) as a second-level predictor and one model that did not; the ICC was calculated for each model. The between-hospital variation for a given outcome that could be attributed to the hospital rate of active treatment was calculated as 1 − [(ICC of model including hospital rate of active treatment) ÷ (ICC of model not including hospital rate of active treatment)]. 25 To account for differences in patient characteristics among hospitals, models were adjusted for the covariates listed previously. For each participating hospital, risk-adjusted outcomes were calculated on the basis of these The New England Journal of Medicine models by means of the marginal method of regression adjustment. 26 In addition, we considered the possibility that hospital volume may explain some of the betweenhospital variation in outcomes; this possibility has been proposed previously. 27, 28 Sensitivity analyses were performed to evaluate whether hospital volume of extremely preterm births during the study period modified the effect of hospital rates of active treatment on outcomes.
Multilevel modeling was performed using Stata/MP software, version 13.0 (StataCorp). All other analyses were performed using SAS software, version 9.3 (SAS Institute). Two-sided P values of less than 0.05 were considered to indicate statistical significance.
R esult s

Infant Characteristics
A total of 4987 infants born at 24 hospitals were included in the study (range, 32 to 489 infants per hospital), of whom 4329 (86.8%) received active treatment ( Table 1) . Infants who did not receive active treatment after birth were more likely to be small for gestational age and to have 1-minute Apgar scores of 3 or lower; they were less likely to have been exposed to antenatal glucocorticoids or to have been delivered by cesarean section. Methods of active treatment varied by gestational age at birth (see Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
Active treatment was administered to 22.1% (95% confidence interval [CI], 18.1 to 26.8) of infants born at 22 weeks of gestation, 71.8% (95% CI, 68.5 to 74.9) born at 23 weeks of gestation, 97.1% (95% CI, 96.0 to 98.0) born at 24 weeks of gestation, 99.6% (95% CI, 99.1 to 99.8) born at 25 weeks of gestation, and 99.8% (95% CI, 99.4 to 100.0) born at 26 weeks of gestation. Among infants born at 22 or 23 weeks of gestation, overall rates of active treatment were significantly higher among infants born on the last 2 days of the gestational week than among those born earlier during the same week ( Fig. 1) .
Outcomes were known for 4704 children (94.3%) at 18 to 22 months of corrected age (Table 2). Among those who received active treatment and whose outcomes were known at follow-up (4046 children), 65.0% survived, 56.1% survived without severe neurodevelopmental im-pairment, and 40.8% survived without moderate or severe neurodevelopmental impairment. Detailed outcomes for children who survived are described in Table S2 in the Supplementary Appendix. All infants who did not receive active treatment (658 infants) died within 24 hours after birth.
Two of 129 infants born before 22 weeks of gestation who weighed 400 g or more received active treatment. These patients were born at 21 weeks 0 days and at 21 weeks 4 days, at different hospitals. All infants born before 22 weeks of gestation died within 12 hours after birth.
Variation in Hospital Rates of Active Treatment
Among infants born at 22, 23, or 24 weeks of gestation, hospital rates of active treatment varied widely ( Fig. S1 in the Supplementary Appendix). The interquartile ranges for hospital rates of active treatment were 7.7 to 100% among infants born at 22 weeks of gestation, 52.5 to 96.5% among infants born at 23 weeks of gestation, and 95.2 to 100% among infants born at 24 weeks of gestation. Most hospitals provided active treatment to all infants born at 25 or 26 weeks of gestation (interquartile range, 100 to 100%); 5 of 24 hospitals provided active treatment to all infants born at 22 through 26 weeks of gestation.
Results from multilevel models indicated that the initiation of active treatment clustered at the hospital level. The proportion of variation in hospital rates of active treatment that was attributable to the infant's hospital of birth was 71% (ICC, 0.71; 95% CI, 0.45 to 0.88), 38% (ICC, 0.38; 95% CI, 0.21 to 0.58), and 25% (ICC, 0.22; 95% CI, 0.06 to 0.57) for infants born at 22, 23, or 24 weeks of gestation, respectively, after adjustment for patient demographic and clinical factors. There was no significant variation in hospital rates of active treatment among infants born at 25 or 26 weeks of gestation.
Relationship of Active Treatment to Outcomes
Overall rates of survival, survival without severe impairment, and survival without moderate or severe impairment were 5.1% (interquartile range, 0 to 10.6), 3.4% (interquartile range, 0 to 6.9), and 2.0% (interquartile range, 0 to 0.7), respectively, among children born at 22 weeks of gestation and were 23.1% (interquartile range, 0 to The discrepancy between outcomes for all children and outcomes for those who received active treatment decreased with increasing gestational age at birth ( Table 2 ). Figure 2 shows the relationship of hospital rates of active treatment to risk-adjusted outcomes for children born at 22, 23, or 24 weeks of gestation. Multilevel models did not converge when children born at 22 weeks of gestation and those born at 23 weeks of gestation were considered separately, and thus children born at either 22 or 23 weeks of gestation were included in the same model. Among children born at 22 or 23 weeks of gestation, the hospital rate of active treatment accounted for a majority of the between-hospital variation in outcomes (78% of the variation in survival, 75% of the variation in survival without severe impairment, 41% of the variation in survival without moderate or severe impairment), after adjustment for patient clinical and demographic factors; this relationship was attenuated among those born at 24 weeks. Among children born at 25 or 26 weeks, hospital rates of active treatment did not account for between-hospital variation in outcomes (Table 3 ). Furthermore, there was no significant relationship between hospital volume of extremely preterm births and survival outcomes in any of our models (P>0.8 for all comparisons), and hospital volume of extremely preterm infants did not significantly mod-ify the relationship between hospital rates of active treatment and outcomes.
Discussion
In this cohort of extremely preterm infants born at U.S. hospitals included in the NICHD NRN, we found significant between-hospital variation 
1808
T h e ne w e ngl a nd jou r na l o f m e dicine in the rates of initiating potentially lifesaving treatment after birth. Differences in hospital rates of active treatment among children born at 22, 23, or 24 weeks of gestation explained a large portion of the variation in hospital rates of survival and survival without severe impairment and explained a lesser portion of the variation in hospital rates of survival without moderate or severe impairment. Best obstetrical estimates of gestational age for most pregnancies (except those conceived through in vitro fertilization) have a margin of error of at least 5 days, 29 and error may be greater for pregnancies resulting in extremely preterm birth. 30, 31 Yet, we found that rates of active treatment among infants born at the end of 22 or 23 weeks of gestation were significantly higher than the rates among infants born earlier during the same weeks. Our findings suggest that physicians and families may "round up" when considering gestational age in the decision to initiate potentially lifesaving treatment.
Hospitals at which active treatment was more often initiated had higher rates of risk-adjusted survival both with and without impairment than did hospitals at which active treatment was less frequently initiated. However, differences in hospital rates of active treatment did not account for all variation in outcomes. Among hospitals that initiated treatment for 100% of infants born at 24 weeks of gestation, for example, rates of riskadjusted survival still varied from 42.4 to 69.9%. Further research is needed to identify other factors contributing to the variation in outcomes.
In our study, we assessed important outcomes using data collected for a large prospective cohort of liveborn infants with a high follow-up rate to provide information about the scope of between-hospital variation in care for extremely preterm infants in the United States. Although composite outcomes for severe and moderate impairment were necessary to make statistical comparisons, their components do not have equivalent importance to patients or their families, and this should be taken into consideration in interpreting our results. Moreover, standardized Bayley-III scores at 18 to 22 months of corrected age may not fully predict developmental outcomes later in childhood. [32] [33] [34] Other limitations of our study are that our models may not have accounted for some clinical and demographic factors associated with between-hospital variation in outcomes and that we do not have sufficient data to construct a denominator of all births -both live births and stillbirths -at participating hospitals.
Neurodevelopmental impairment is an outcome of particular concern to patients, families, and clinicians when considering whether to initiate or forgo treatment in extremely preterm infants. Perceptions of the risk of impairment significantly influence decisions about initiating treatment in infants born at early gestational ages. 35 Although we found that decisions to initiate active treatment cluster at the hospital level for in-fants born at 22, 23, or 24 weeks of gestation, we are unable to determine whether between-hospital variation resulted from clustering of family preferences, hospital culture, hospital policy, or other factors. We do not have information regarding when (i.e., before or after birth) or how decisions about the initiation of active treatment were made and cannot determine whether variation in rates of active treatment resulted from differences in understanding of possible outcomes or from varying perspectives regarding the value of survival as compared with the risk of impairment.
Hospital-level outcomes data that are used to counsel families about the benefits and burdens of initiating treatment are influenced by local approaches to initiating treatment. Outcome statistics that are derived from populations that include large numbers of infants who did not receive active treatment may seem to support decisions to forgo future treatment, resulting in a "self-fulfilling" prognosis. [36] [37] [38] For transparency and accuracy, it is important to take into account whether the infants included in outcome statistics received active treatment when using those data to counsel families. 39 Our results highlight considerable variation in hospital practices regarding the initiation of active treatment in infants born at 22, 23, or 24 weeks of gestation. Differences in practices regarding the initiation of active treatment in extremely preterm infants appear to explain a large portion of the between-hospital variation in survival among such patients and a substantial but lesser portion of the variation in survival without neurodevelopmental impairment.
